File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0140-6736(23)00020-X
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Article: Thyroid cancer
Title | Thyroid cancer |
---|---|
Authors | |
Issue Date | 1-Apr-2023 |
Publisher | Elsevier |
Citation | The Lancet, 2023, v. 401, n. 10387, p. 1531-1544 How to Cite? |
Abstract | The past 5–10 years have brought in a new era in the care of patients with thyroid cancer, with the introduction of transformative diagnostic and management options. Several international ultrasound-based thyroid nodule risk stratification systems have been developed with the goal of reducing unnecessary biopsies. Less invasive alternatives to surgery for low-risk thyroid cancer, such as active surveillance and minimally invasive interventions, are being explored. New systemic therapies are now available for patients with advanced thyroid cancer. However, in the setting of these advances, disparities exist in the diagnosis and management of thyroid cancer. As new management options are becoming available for thyroid cancer, it is essential to support population-based studies and randomised clinical trials that will inform evidence-based clinical practice guidelines on the management of thyroid cancer, and to include diverse patient populations in research to better understand and subsequently address existing barriers to equitable thyroid cancer care. |
Persistent Identifier | http://hdl.handle.net/10722/328301 |
ISSN | 2023 Impact Factor: 98.4 2023 SCImago Journal Rankings: 12.113 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chen, DW | - |
dc.contributor.author | Lang, HHB | - |
dc.contributor.author | McLeod, DSA | - |
dc.contributor.author | Newbold, K | - |
dc.contributor.author | Haymart, MR | - |
dc.date.accessioned | 2023-06-28T04:41:38Z | - |
dc.date.available | 2023-06-28T04:41:38Z | - |
dc.date.issued | 2023-04-01 | - |
dc.identifier.citation | The Lancet, 2023, v. 401, n. 10387, p. 1531-1544 | - |
dc.identifier.issn | 0140-6736 | - |
dc.identifier.uri | http://hdl.handle.net/10722/328301 | - |
dc.description.abstract | <p>The past 5–10 years have brought in a new era in the care of patients with thyroid cancer, with the introduction of transformative diagnostic and management options. Several international ultrasound-based thyroid nodule risk stratification systems have been developed with the goal of reducing unnecessary biopsies. Less invasive alternatives to surgery for low-risk thyroid cancer, such as active surveillance and minimally invasive interventions, are being explored. New systemic therapies are now available for patients with advanced thyroid cancer. However, in the setting of these advances, disparities exist in the diagnosis and management of thyroid cancer. As new management options are becoming available for thyroid cancer, it is essential to support population-based studies and randomised clinical trials that will inform evidence-based clinical practice guidelines on the management of thyroid cancer, and to include diverse patient populations in research to better understand and subsequently address existing barriers to equitable thyroid cancer care.<br></p> | - |
dc.language | eng | - |
dc.publisher | Elsevier | - |
dc.relation.ispartof | The Lancet | - |
dc.title | Thyroid cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/S0140-6736(23)00020-X | - |
dc.identifier.hkuros | 344752 | - |
dc.identifier.volume | 401 | - |
dc.identifier.issue | 10387 | - |
dc.identifier.spage | 1531 | - |
dc.identifier.epage | 1544 | - |
dc.identifier.eissn | 1474-547X | - |
dc.identifier.issnl | 0140-6736 | - |